Evidence map›Paper›PMID 42138077›Full record

Trial reportThe Journal of clinical investigation2026

Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters.

Gaelle Haddad, Junyu Guo, Yin Xi, Emin Albayrak, Mahrukh Huseni, Habib Hamidi, Romain Banchereau, Edward Kadel, Sarita Dubey, Corey Carter and 3 more

Abstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gaelle HaddadDepartment of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Junyu GuoDepartment of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Yin XiDepartment of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Emin AlbayrakDepartment of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Mahrukh HuseniGenentech, San Francisco, California, USA.
Habib HamidiGenentech, San Francisco, California, USA.
Romain BanchereauGenentech, San Francisco, California, USA.
Edward KadelGenentech, San Francisco, California, USA.
Sarita DubeyGenentech, San Francisco, California, USA.
Corey CarterGenentech, San Francisco, California, USA.
Payal KapurDepartment of Pathology.
James BrugarolasKidney Cancer Program.
Ivan PedrosaDepartment of Radiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUNDThe relationship between molecular subgroups in clear-cell renal cell carcinoma (ccRCC) and metastatic tropism is poorly understood.METHODSWe analyzed over 5,000 metastatic sites from 305 treatment-naive ccRCC patients in the IMmotion150 phase II clinical trial, where patients were randomized to atezolizumab, atezolizumab/bevacizumab, or sunitinib.RESULTSAngiogenic tumors (clusters 1 and 2) had a higher rate of pancreatic (21% vs. 6.9%; P = 0.002) and lower absolute number of lymph node (2.5 vs. 4.2; P = 0.006) metastases. In contrast, proliferative tumors (clusters 4 and 5) exhibited a higher absolute number of lymph node metastases (5.5 vs. 3.5; P = 0.019). Patients with pancreatic metastases receiving sunitinib had higher odds of overall response (OR, 7.13; 95% CI, 1.81-28.07; P = 0.0049) and longer progression-free survival than those without pancreatic metastases (P = 0.02).CONCLUSIONccRCC metastatic tropism relates to molecular clusters that predict response to therapy for tumors that metastasize to the pancreas.TRIAL REGISTRATIONClinicalTrials.gov NCT01984242FUNDINGNIH grants R01CA154475 and P50CA196516.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsPancreatic NeoplasmsAgedAntibodies, Monoclonal, HumanizedBevacizumabFemaleHumansLymphatic MetastasisMaleMiddle AgedSunitinibAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabSunitinibCancerClinical ResearchDiagnostic imagingMolecular geneticsOncologyPublic Health

Identifiers

PMID42138077
PMCPMC13178644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.